{"nctId":"NCT01987505","briefTitle":"MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma","startDateStruct":{"date":"2013-11-11","type":"ACTUAL"},"conditions":["Lymphoma, Non Hodgkin"],"count":140,"armGroups":[{"label":"Subcutaneous Rituximab","type":"EXPERIMENTAL","interventionNames":["Drug: Rituximab"]}],"interventions":[{"name":"Rituximab","otherNames":["MabThera","Rituxan"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age ≥ 18 and ≤ 80 years at time of enrolment.\n* Life expectancy ≥ 6 months.\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 3.\n* Fertile men or women of childbearing potential must use effective contraception until at least 12 months after the last dose; women must not be pregnant.\n* Histologically confirmed CD20+ diffuse large B-cell lymphoma (DLBCL) or CD20+ follicular Non-Hodgkin Lymphoma (FL) grade 1, 2 or 3a according to the World Health Organisation Classification system.\n\nInduction only:\n\n* Participants with Follicular Lymphoma should meet Groupe D'Etude des Lymphomes Folliculaires (GELF) criteria to initiate treatment.\n* At least tumor \\>/= 1.5 cm as measured by computed tomography (CT) scan.\n\nFL treatment-related criteria\n\n\\- Currently being treated with rituximab IV during first-line therapy and has received at least one full dose of rituximab IV.\n\nExclusion Criteria:\n\n* Transformed lymphoma.\n* Primary central nervous system lymphoma, primary effusion lymphoma, primary mediastinal DLBCL, DLBCL of the testis, primary cutaneous DLBCL or histologic evidence of transformation to a Burkitt lymphoma.\n* History of other cancer, including one that has been treated but not with curative intent, unless the cancer has been in remission without treatment for \\>/= 5 years prior to dosing. Note: Participants with a history of cured skin cancer or in situ carcinoma of the cervix are eligible for the study.\n* Ongoing corticosteroid use \\> 30 mg/day of prednisone or equivalent. Note: Participants receiving corticosteroid treatment with \\</= 30 mg/day of prednisone or equivalent must be on a stable regimen for at least 4 weeks prior to start of dosing.\n* Inadequate renal, hematologic, or hepatic function.\n* History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products.\n* For participants with DLBCL: Contraindication to any of the individual components of CHOP (cyclophosphamide, vincristine, doxorubicin and prednisone), including prior anthracycline treatment.\n* For participants with FL: contraindication to standard chemotherapy.\n* Other serious underlying medical conditions.\n* Recent major surgery (within 4 weeks prior to dosing), other than for diagnosis.\n* Active and/or severe infections (excluding nail fungal infections) or any infection requiring treatment with IV antibiotics or hospitalization within 4 weeks prior to dosing.\n* Active Hepatitis B virus (HBV) or Hepatitis C virus (HCV) infection. Note: Participants testing positive for Hepatitis B or C virus antibodies but with an undetectable viral load may be included.\n* History of Human Immunodeficiency Virus (HIV) positive status.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Administration-Associated Reactions (AARs)","description":"AARs were defined as all adverse events (AEs) occurring within 24 hours of rituximab SC administration and which were considered related to study drug. AARs included infusion/injection-related reactions (IIRRs), injection-site reactions, administration site conditions and all symptoms thereof. Grading was completed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.5","spread":null},{"groupId":"OG001","value":"52.3","spread":null},{"groupId":"OG002","value":"48.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2.7","spread":null},{"groupId":"OG002","value":"2.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1.8","spread":null},{"groupId":"OG002","value":"1.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.9","spread":null},{"groupId":"OG001","value":"11.1","spread":null},{"groupId":"OG002","value":"15.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.1","spread":null},{"groupId":"OG001","value":"88.9","spread":null},{"groupId":"OG002","value":"84.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With At Least One Grade >/= 3 Adverse Events (AEs)","description":"An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsen during a study are also considered as adverse events. Grading was completed according to the CTCAE, version 4.0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.3","spread":null},{"groupId":"OG001","value":"36.0","spread":null},{"groupId":"OG002","value":"38.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With At Least One Grade >/= 3 Infusion/ Injection Related Reactions (IIRRs)","description":"Grading of IIRRs was completed according to the CTCAE, version 4.0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"2.7","spread":null},{"groupId":"OG002","value":"2.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With At Least One Serious Adverse Event (SAE)","description":"SAE was defined as any experience that suggested a significant hazard, contraindication, side effect, or precaution, and fulfilled any of the following criteria: fatal (resulted in death), life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/ birth defect, was medically significant or required intervention to prevent any of the other outcomes listed here.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.9","spread":null},{"groupId":"OG001","value":"27.9","spread":null},{"groupId":"OG002","value":"30.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Event-Free Survival (EFS)","description":"EFS was defined as the time from first dose of rituximab IV to first occurrence of progressive disease (PD) or relapse, according to the International Working Group (IWG) response criteria or initiation of a non-protocol-specified anti-lymphoma therapy or death, whichever occurs first. PD: \\>/= 50% increase lymph nodes and nodal mass size, any new lesion, enlarged liver/spleen, reappearance bone marrow abnormalities.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.79","spread":null},{"groupId":"OG001","value":"54.39","spread":null},{"groupId":"OG002","value":"52.314","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-Free Survival (PFS)","description":"PFS was defined as the time from first dose of rituximab IV to the first occurrence of progressive disease (PD) or relapse, according to the International Working Group (IWG) response criteria or death from any cause. PD: \\>/= 50% increase lymph nodes and nodal mass size, any new lesion, enlarged liver/spleen, reappearance bone marrow abnormalities.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.952","spread":null},{"groupId":"OG001","value":"54.389","spread":null},{"groupId":"OG002","value":"53.118","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS was defined as the time from first dose of rituximab IV to death from any cause.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.42","spread":null},{"groupId":"OG001","value":"60.61","spread":null},{"groupId":"OG002","value":"59.516","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease-Free Survival (DFS)","description":"DFS was assessed in participants achieving complete response (CR) including complete response unconfirmed (Cru) and was defined as the period from the date of the initial CR/CRu until the date of relapse or death from any cause. CR: 1) disappearance of all evidence/symptoms of disease, 2) lymph nodes and nodal masses normal size, 3) enlarged spleen must have regressed in size, 4) normal bone marrow; CRu: see 1) and 3) of CR plus \\> 75% decrease in residual lymph node mass, indeterminate bone marrow. Reported here is the truncated mean estimate based on Kaplan-Meier analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.062","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"33.044","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Response Rate","description":"Treatment response rate was classified according to the International Working Group (IWG) response criteria: CR/Cru, partial response (PR), stable disease (SD) and PD. CR: 1) disappearance of all evidence/symptoms of disease, 2) lymph nodes and nodal masses normal size, 3) enlarged spleen must have regressed in size, 4) normal bone marrow; CRu: see 1) and 3) of CR plus \\> 75% decrease in residual lymph node mass, indeterminate bone marrow; PR: \\>/= 50% decrease lymph nodes and nodal mass size; decrease in liver/spleen size, no new sites; SD: less than a PR, but is not PD; PD: \\>/= 50% increase lymph nodes and nodal mass size, any new lesion, enlarged liver/spleen, reappearance bone marrow abnormalities.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.1","spread":null},{"groupId":"OG001","value":"66.7","spread":null},{"groupId":"OG002","value":"64.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":null},{"groupId":"OG001","value":"7.4","spread":null},{"groupId":"OG002","value":"5.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":null},{"groupId":"OG001","value":"11.1","spread":null},{"groupId":"OG002","value":"7.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"3.7","spread":null},{"groupId":"OG002","value":"1.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.2","spread":null},{"groupId":"OG001","value":"7.4","spread":null},{"groupId":"OG002","value":"12.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"3.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":null},{"groupId":"OG001","value":"3.7","spread":null},{"groupId":"OG002","value":"5.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":42,"n":140},"commonTop":["Erythema","Asthenia","Neutropenia","Respiratory tract infection","Diarrhoea"]}}}